- Conditions
- Elevated Intraocular Pressure
- Interventions
- Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
- Drug
- Lead sponsor
- TearClear Corp
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 20
- States / cities
- Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 1,356
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Open-angle Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- VSJ-110, Placebo
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3)
- Interventions
- DCR-PHXC
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- LCD, calcipotriol
- Drug
- Lead sponsor
- NeoStrata Company, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- TAK-648 Tablet, TAK-648 Oral Solution
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Dry Eye Disease
- Interventions
- Naltrexone, Placebos
- Drug
- Lead sponsor
- Sassani, Joseph S., MD, MHA
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Nashville, Tennessee
- Conditions
- Bacterial Infections, Eye Infections
- Interventions
- AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
- Interventions
- AZLI, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 12
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more
- Conditions
- Hematologic Diseases, Stem Cell Transplants
- Interventions
- PUL-042
- Drug
- Lead sponsor
- Pulmotect, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Yellow Fever Vaccine
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Distal and Lateral Subungual Onychomycosis
- Interventions
- Luliconazole Solution, 10%, Vehicle Solution
- Drug
- Lead sponsor
- Topica Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
- Conditions
- Rett Syndrome, RTT
- Interventions
- GWP42003-P
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more
- Conditions
- Colonoscopy
- Interventions
- Olympus colonoscope, Irrigation solution
- Device · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dentin Hypersensitivity
- Interventions
- 3M™ Clinpro™ Fluoride Aqueous Solution, 3M™ Vanish™
- Device
- Lead sponsor
- Solventum US LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Type 2 Diabetes
- Interventions
- Online Diabetes Self-Management Education and Support (DSMES) Program, Standard of Care
- Behavioral
- Lead sponsor
- Omada Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Neuropathic Corneal Pain
- Interventions
- Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution
- Drug · Other
- Lead sponsor
- Okyo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pain
- Interventions
- 2% w/w diclofenac sodium topical gel, 1.5% w/w diclofenac sodium topical solution, 75 mg diclofenac sodium delayed release tablet
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 99
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more
- Conditions
- Obstetric Labour, Premature, Premature Ejaculation
- Interventions
- GSK221149
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Diabetic Macular Edema, Age-related Macular Degeneration
- Interventions
- MTP-131
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts